Vontobel Financial Products GmbH News - F29049

Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease

Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease - Merck Serono to Develop Domain...

Brighter Futures in MS - Inspiring Short Film Premieres in Brussels

Brighter Futures in MS - Inspiring Short Film Premieres in Brussels PR Newswire GENEVA and BRUSSELS, January 12, 2011 GENEVA and BRUSSELS...

Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases

Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases PR Newswire GENEVA, December 13, 2010...

Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Mu

Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple...

Merck Serono: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS

Merck Serono: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS PR Newswire GENEVA, November...

Merck Serono: Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe

Merck Serono: Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe - Saizen(R) Solution For Injection...

Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's

Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's Disease PR...

Merck Serono Sells Théramex to Teva for EUR 265 Million

Merck Serono Sells Théramex to Teva for EUR 265 Million - Acquisition Will Provide Teva With a Strong Platform to Expand its Global Women's...

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of the Disease...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Vontobel Financial Products GmbH (F29049)

Professional-Grade Tools, for Individual Investors.

F29049 News

Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease

Brighter Futures in MS - Inspiring Short Film Premieres in Brussels

Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases

Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Mu

Merck Serono: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS

Merck Serono: Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe

Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's

Merck Serono Sells Théramex to Teva for EUR 265 Million

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of

Merck Serono to Introduce RebiDose(TM), the Rebif(R) Single Use Pre-filled Pen for Treatment of Multiple Sclerosis

Merck Serono: New Presentation of Cyanokit(R) Approved in Europe

Merck Serono Notified EMA of its Intention to Appeal CHMP Opinion on Cladribine Tablets in MS

Ablynx and Merck Serono Enter into Second Agreement To Co-Discover and Co-Develop Nanobodies (R)

Merck Serono Calls for Entries to Real MS - Your Story, a Global Competition to Raise Awareness of Multiple Sclerosis

Merck Serono: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS

F29049 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Vontobel Financial Products GmbH (F29049) News

Vontobel Financial Products GmbH (F29049)

Professional-Grade Tools, for Individual Investors.

F29049 News

Merck Serono and Domain Therapeutics Announce an Agreement to Develop Drugs for Parkinson's Disease

Brighter Futures in MS - Inspiring Short Film Premieres in Brussels

Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases

Merck Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Mu

Merck Serono: Enrollment Completed for ORACLE MS Study of Cladribine Tablets in Patients at Risk of Developing MS

Merck Serono: Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe

Merck Serono Announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson's

Merck Serono Sells Théramex to Teva for EUR 265 Million

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of

Merck Serono to Introduce RebiDose(TM), the Rebif(R) Single Use Pre-filled Pen for Treatment of Multiple Sclerosis

Merck Serono: New Presentation of Cyanokit(R) Approved in Europe

Merck Serono Notified EMA of its Intention to Appeal CHMP Opinion on Cladribine Tablets in MS

Ablynx and Merck Serono Enter into Second Agreement To Co-Discover and Co-Develop Nanobodies (R)

Merck Serono Calls for Entries to Real MS - Your Story, a Global Competition to Raise Awareness of Multiple Sclerosis

Merck Serono: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS

F29049 Discussion

Your Recent History